Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Appointed director
Poseida Therapeutics, Inc. (PSTX) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/08/2023 8-K Quarterly results
Docs: "Investor Contact:"
08/07/2023 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...
Docs: "Securities Purchase Agreement, by and between the Company and Astellas",
"Registration Rights Agreement, by and between the Company and Astellas",
"CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.",
"Investor Contact:",
"Investor Contact:"
06/16/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/01/2023 8-K Termination of a Material Definitive Agreement, Other Events  Interactive Data
05/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
03/09/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Investor Contact:"
02/22/2023 8-K Quarterly results
01/31/2023 8-K Quarterly results
12/06/2022 8-K Quarterly results
12/01/2022 8-K Quarterly results
11/10/2022 8-K Quarterly results
09/07/2022 8-K Other Events  Interactive Data
08/11/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
08/03/2022 8-K Results of Operations and Financial Condition, Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
08/03/2022 8-K Investor presentation
Docs: "Poseida Therapeutics Announces Strategic Global Collaboration with Roche Focused on Allogeneic CAR-T Cell Therapies for Hematologic Malignancies",
"Presentation of Poseida Therapeutics, Inc."
06/16/2022 8-K Quarterly results
05/18/2022 8-K Quarterly results
05/12/2022 8-K Quarterly results
04/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/10/2022 8-K Results of Operations and Financial Condition, Departure of Directors or Certain Officers; Election of Directors; Appointment...
Docs: "Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2021 Company announced first strategic collaboration with Takeda focused on deploying its platform technologies to develop non-viral in vivo gene therapies"
02/23/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate presentation",
"Corporate presentation"
02/22/2022 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Ob...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/17/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Poseida Therapeutics to Present Interim Results from Phase 1 Trial of P-PSMA-101 at ASCO Genitourinary Cancers Symposium",
"Presentation of Poseida Therapeutics, Inc."
02/01/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amended and Restated Executive Employment Agreement, by and between the Company and Mark Gergen",
"Amended and Restated Participation Agreement, by and between the Company and Mark Gergen",
"Amended and Restated Executive Employment Agreement, by and between the Company and Eric Ostertag, M.D., Ph.D.",
"Amended and Restated Participation Agreement, by and between the Company and Eric Ostertag, M.D., Ph.D."
01/10/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
11/09/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Poseida Therapeutics Provides Program Updates and Financial Results for the Third Quarter of 2021 Clearance of IND by FDA and clinical trial start-up for P-BCMA-ALLO1 begins planned strategic shift to allogeneic BCMA CAR-T program for patients with multiple myeloma; P-BCMA-101 autologous CAR-T program to be wound down"
10/13/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/12/2021 8-K Entry into a Material Definitive Agreement  Interactive Data
08/31/2021 8-K Quarterly results
08/12/2021 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "Poseida Therapeutics Reports Program Updates and Financial Results for the Second Quarter of 2021"
06/17/2021 8-K Submission of Matters to a Vote of Security Holders
05/11/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy